In eukaryotes, the anaphase-promoting complex (APC/C, also known as the cyclosome) regulates the ubiquitin-dependent proteolysis of specific cell-cycle proteins to coordinate chromosome segregation in mitosis and entry into the G1 phase 1,2 . The catalytic activity of the APC/C and its ability to specify the destruction of particular proteins at different phases of the cell cycle are controlled by its interaction with two structurally related coactivator subunits, Cdc20 and Cdh1. Coactivators recognize substrate degrons 3 , and enhance the affinity of the APC/C for its cognate E2 (refs 4-6). During mitosis, cyclin-dependent kinase (Cdk) and polo-like kinase (Plk) control Cdc20-and Cdh1-mediated activation of the APC/C. Hyperphosphorylation of APC/C subunits, notably Apc1 and Apc3, is required for Cdc20 to activate the APC/C 7-12 , whereas phosphorylation of Cdh1 prevents its association with the APC/C 9,13,14 . Since both coactivators associate with the APC/C through their common C-box 15 and Ile-Arg tail motifs 16,17 , the mechanism underlying this differential regulation is unclear, as is the role of specific APC/C phosphorylation sites. Here, using cryo-electron microscopy and biochemical analysis, we define the molecular basis of how phosphorylation of human APC/C allows for its control by Cdc20. An auto-inhibitory segment of Apc1 acts as a molecular switch that in apo unphosphorylated APC/C interacts with the C-box binding site and obstructs engagement of Cdc20. Phosphorylation of the auto-inhibitory segment displaces it from the C-box-binding site. Efficient phosphorylation of the autoinhibitory segment, and thus relief of auto-inhibition, requires the recruitment of Cdk-cyclin in complex with a Cdk regulatory subunit (Cks) to a hyperphosphorylated loop of Apc3. We also find that the small-molecule inhibitor, tosyl-l-arginine methyl ester, preferentially suppresses APC/C Cdc20 rather than APC/C
. These sites lie within disordered regions of the APC/C 23 . Incubating the APC/C with both Cdk2-cyclin A3-Cks2 and Plk1 simultaneously was necessary to obtain full activation (Extended Data Fig. 1b) . Consistent with ref. 12 , treatment with Cdk2-cyclin A3-Cks2 alone resulted in lower APC/C activation, whereas phosphorylation with Plk1 alone did not activate the APC/C.
To gain insights into the molecular interactions between Cdc20 and mitotic APC/C, a ternary complex was assembled using phosphorylated APC/C, Cdc20 and a high-affinity substrate Hsl1 (APC/C Cdc20-Hsl1 ) (Extended Data Fig. 1d ) for cryo-EM analysis ( Table 1 ). Owing to the low occupancy of Cdc20 bound to the APC/C, combined with conformational heterogeneity, only 9% of the particles were used for the final reconstruction of APC/C Cdc20-Hsl1 , with the remainder being in either the apo state (72%) or in a hybrid state (Extended Data Fig. 2 ). Most static regions of the complex extend beyond 3.9 Å resolution, whereas the catalytic module (Apc2 and Apc11), as well as the WD40 domain of Cdc20, are more flexible (Extended Data Fig. 3a) .
APC/C Cdc20-Hsl1 adopts an active conformation with the catalytic module in the upward position reminiscent of APC/C Cdh1-Hsl1 (ref. 6) ( NTD forms fewer contacts with both Apc1 and Apc8B ( Fig. 1c-e) . However, the crucial C-box motif (DRYIPxR) represents a structurally conserved region common to both coactivators (Fig. 1d , Extended Data Figs 3c, d and 4d). Cdc20 C box forms a network of electrostatic interactions with Apc8B, centred on the crucial Arg78 (ref. 23) , and augmented by non-polar interactions involving its Tyr79 and Ile80 residues (Fig. 1d) . A KILR motif also present within Cdc20 NTD is essential for Cdc20 association with the APC/C (ref. 25 ) and the APC/C Cdc20-Hsl1 structure reveals that Ile130 and Leu131 of Cdc20 KILR are inserted into a hydrophobic pocket of the TPR (tetratricopeptide repeat) superhelix of Apc8B, further stabilizing the conformation of the C box (Fig. 1e ). Similar C-box stabilization is present in Cdh1 NTD , but is instead provided by a loop structurally unrelated to Cdc20 KILR (Fig. 1c ) 23 . By contrast, the KLLR-motif of Cdh1 NTD is located in a leucine-zipper-like α -helix (α 3) that forms a hydrophobic interface with Apc1 (ref. 23) (Fig. 1c and Extended Data Fig. 4d ). The absence of an equivalent to the Cdh1 α 3 helix in Cdc20 suggests a weaker mode of binding of Cdc20 NTD relative to Cdh1 NTD .
EM density for Cdc20
IR is weaker than for Cdh1 IR and it lacks the associated α -helix of Cdh1 IR (Extended Data Fig. 3e ). This could account for the lower affinity of the APC/C for Cdc20 IR compared with Cdh1 IR (ref. 17) . Nonetheless, the crucial Ile-Arg interaction of Cdc20 IR with the TPR superhelix of Apc3A is conserved between the two coactivators (Extended Data Fig. 3e ). Importantly, because in the APC/C are not visible, we find no evidence that phosphorylated regions of the APC/C either directly or indirectly contact Cdc20. This suggested that APC/C phosphorylation invokes a conformational change of apo APC/C that promotes its association with Cdc20.
To explore this possibility, we determined cryo-EM structures of apo APC/C in both the unphosphorylated and phosphorylated states at near-atomic resolution (Fig. 2a, b , Extended Data Fig. 5a , b, Extended Data Table 1 and Supplementary Video 1). In both states, the catalytic module adopts an inactive conformation (Extended Data Fig. 4a, b) as seen in the previous 8 Å resolution reconstruction 6 . However, threedimensional classification of the atomic resolution EM maps of both apo states showed that the majority of Apc3A adopts a closed conformation resembling the Apc3 crystal structure in which an α -helix (TPR12A) occupies and blocks the IR tail-binding pocket (Extended Data Fig. 5c ) 26 . In ~ 30% of particles Apc3A adopts an open conformation identical to the IR tail-bound state. Thus inter-conversion of Apc3A between closed and open IR tail-accessible states is not controlled by phosphorylation.
Phosphorylated and unphosphorylated apo APC/C EM maps are very similar in structure (Extended Data Fig. 5a, b) , except for a notable difference in the region of the C-box binding site (Fig. 2c-f) . In unphosphorylated APC/C, an unassigned segment of EM density of ~ 15 residues indicative of an elongated loop connected to a short α -helix is located at the C-box binding pocket of Apc8B (Fig. 2c-e) . The equivalent EM density is not present in phosphorylated APC/C (Fig. 2f) . The WD40 domain of Apc1, positioned in close proximity to this density, incorporates two highly phosphorylated regions (residues 307-395 (300s loop) and residues 515-579 (500s loop)) (Fig. 2c, d and Extended Data Table 2 ), which have not previously been assigned in either APC/C Cdc20-Hsl1 or APC/C Cdh1-Emi1 structures 23 . The 300s loop would be predicted to project towards the C-box binding site of Apc8B (Fig. 2c, d and Extended Data Fig. 5d ), implicating it as a candidate for the unassigned density segment.
We determined the structure of an APC/C mutant with the 300s loop of Apc1 deleted (APC/C ∆Apc1-300s ) ( Fig. 2g and Extended Data Table 1a ). In this structure, the C-box binding pocket of APC/C ∆Apc1-300s is devoid of EM density even without in vitro phosphorylation (Fig. 2g) , consistent with its assignment to the 300s loop. Furthermore, ubiquitination assays showed that APC/C ∆Apc1-300s was constitutively activated by Cdc20 and that phosphorylation did not enhance its activity (Fig. 3a, compare lanes 6, 7 to 8, 9). This indicates that unphosphorylated APC/C is maintained in an auto-inhibited conformation by an Apc1 auto-inhibitory segment, present within the 300s loop that sterically impedes the C-box site from binding Cdc20. In support of this idea, analytical size-exclusion chromatography showed that Cdc20 forms a binary complex with phosphorylated APC/C, but not with unphosphorylated APC/C (Extended Data Fig. 6a ), in agreement with refs 10,12.
To identify the auto-inhibitory segment within the Apc1 300s loop, we synthesized a set of eight overlapping peptides of 20 residues, spanning the 300s loop, and tested their potential to inhibit APC/C ∆Apc1-300s (Fig. 3b) . Notably, peptide 7 (residues 361-380, Fig. 3b , lane 9) potently suppressed Cdc20-dependent APC/C ∆Apc1-300s activity. Interestingly, an Arg368-Phe369 pair of this peptide, that resembles the Arg78-Tyr79 of the C box, is flanked by four serine residues phosphorylated in mitotic APC/C (Fig. 3c and Extended Data Table 2) 12, 21, 22 . EM density for the auto-inhibitory segment is weak, probably due to partial occupancy at the C-box site (Fig. 3c) . Nevertheless, side chain density similar to Arg78-Tyr79 of the C box suggests a fit for the Arg-Phe of peptide 7 (Arg368-Phe369) (Fig. 3c) . To test the possibility that the Apc1 auto-inhibitory segment corresponds to peptide 7, we synthesized mutants of peptide 7 and also introduced the equivalent mutations into Apc1 of the recombinant APC/C. Replacing Arg368 with Glu in Apc1 resulted in a Cdc20-dependent activation of unphosphorylated APC/C (Fig. 3d) , and reduced the inhibitory potency of peptide 7 towards APC/C ∆Apc1-300s (Extended Data Fig. 6c ). A similar result was obtained on substituting glutamates for the four neighbouring serine residues (Ser364, Ser372, Ser373 and Ser377 (APC/C Apc1-4S/E )) to mimic phosphorylation ( Fig. 3d and Extended Data Fig. 6c ). Phosphorylation of Ser377 of peptide 7 relieved the inhibition only partially. These findings suggest that Arg368 anchors the Apc1 auto-inhibitory segment to the C-box binding site, mimicking the Cdc20 C box, and maintaining the apo APC/C in an auto-inhibited state. Phosphorylation of the four neighbouring serine residues would destabilize its association with the C-box site (Figs 3c and 4a ). This mechanism could be further tested in an in vivo context by cellular assays.
Our results so far reveal that the critical determinant of APC/C Cdc20 activation by phosphorylation is displacement of the Apc1 autoinhibitory segment from the C-box site. However, since Apc3 is hyperphosphorylated in mitosis, and Cks stimulates both Cdkdependent activation of APC/C Cdc20 (refs 18,19) and Apc1 and Apc3 domain. Apc11 is modelled based on the APC/ C Cdh1-Emi1 structure (PDB 4UI9) 22 . c, Both Cdc20 NTD (purple) and Cdh1 NTD (grey, aligned to APC/C Cdc20-Hsl1 ) 23 interact with Apc1 and Apc8B, whereas Cdh1
NTD contains an additional α 3 helix associating with Apc1. d, The crucial C-box motif is well conserved between the two coactivators and forms extensive interactions with Apc8B. e, The KLLR motif of Cdh1 is present in the α 3 helix to engage Apc1, whereas the related Cdc20 KILR motif contacts Apc8B to augment C-box binding.
LETTER RESEARCH phosphorylation 18 , and interacts with Apc3 (refs 18,27,28), we tested whether Apc3 phosphorylation also had a role in APC/C activation. In Apc3 about 50 phosphorylation sites are clustered in a large disordered loop comprising residues 180-450 (Extended Data Table 2 ) located on the same face of the APC/C as the Apc1 300s loop (Fig. 2c) . In contrast to APC/C ∆Apc1-300s
, instead of stimulating unphosphorylated APC/C, deletion of the Apc3 loop (APC/C ∆Apc3-loop ) reduced the phosphorylation-mediated activation of APC/C (Fig. 3a, lanes 10-13) . Similarly, Cdk2-cyclin A3 failed to stimulate the APC/C activity in the absence of Cks2 (Extended Data Fig. 1b) . However, combining deletions of both the Apc3 and Apc1 300s loops (APC/C ∆Apc1-300s;Apc3-loop ) restored activity to that of wild-type phosphorylated APC/C (Fig. 3a, lanes 14, 15) . Since deletion of the Apc3 loop disrupts APC/C association with Cdkcyclin-Cks (Extended Data Fig. 1c, lanes 6, 8) , a likely explanation for our results and for the lag phase that accompanies APC/C activation by Cdk1-cyclin B-Cks 19 , is that Apc3 phosphorylation recruits Cdk-cyclin-Cks through Cks 18, 27, 28 to stimulate Apc1 auto-inhibitory segment phosphorylation. Cdk-cyclin-Cks association with the Apc3 loop would allow for a kinetically more efficient intra-molecular phosphorylation of the Apc1 auto-inhibitory segment that only becomes accessible to Cdk when transiently displaced from the C-box site (Figs 3c and 4a) .
To determine whether Apc3 loop-mediated interactions with the Cks2 subunit facilitated Apc1 300s loop phosphorylation, we analysed phosphorylation of the Apc1 300s loop in conditions where such interactions are disrupted. Either deletion of the Apc3 loop or omission of the Cks2 subunit from the phosphorylation reaction, conditions that reduce APC/C activation ( Fig. 3a and Extended Data Fig. 1b) , resulted in the same reduction of Apc1 300s loop phosphorylation (Extended Data Table 2 ). Specifically, mitotic phospho-sites associated with relief of auto-inhibition (Ser364, Ser372 and Ser373) (Extended Data Table 2 , columns 3 and 8) are not modified when Cdk targeting to Apc3 is disrupted (Extended Data Table 2 , columns 4 and 5). In agreement with 12, 22 Ser362 and Ser364 are phosphorylated by Plk1 and Cdk2-cyclin A3-Cks2, respectively, indicating that Ser364 phosphorylation confers partial activation, whereas phosphorylation of Ser372 and Ser373 requires the presence of both kinases, possibly owing to interdependent priming reactions. Since the stimulatory phospho-Ser364 of the auto-inhibitory segment (Fig. 3c) is a non Cdk-consensus site, the relaxed specificity of Cdk2-cyclin A3-Cks2 phosphorylation of this site may be conferred through targeting of the kinase to the APC/C through the Apc3 loop.
Cdc20 and Cdh1 bind to common sites on the APC/C yet only Cdc20 association is regulated by APC/C phosphorylation. In agreement with ref. 9 , we find that Cdh1 activates unphosphorylated and phosphorylated APC/C to a similar extent (Extended Data  Fig. 6d, e) . Comparing unphosphorylated APC/C and APC/C ∆Apc1-300s
we detect some stimulation with APC/C ∆Apc1-300s at low Cdh1 concentrations (Extended Data Fig. 6e ). This is consistent with the enhancement of Cdh1 binding to phosphorylated APC/C and APC/C ∆Apc1-300s (Extended Data Fig. 6b ). Testing the phosphorylationdependent activity of a set of Cdc20-Cdh1 chimaeras indicated that the more extensive interactions involving Cdh1 and the APC/C, mediated by both Cdh1 NTD and Cdh1 IR (Extended Data Fig. 6d) , with a contribution from the Cdh1 NTD α 3 helix (Fig. 1c  and Extended Data Fig. 6f ) , account for the capacity of Cdh1 to activate unphosphorylated APC/C. Although Cdh1 association would also require displacement of the Apc1 auto-inhibitory segment, a potential mechanism to explain the dependency of Cdc20 on APC/C phosphorylation is that the higher affinity of Cdh1 for the Apc8B   TPR11B   TPR11A   TPR7A   TPR7B   TPR8A   TPR10A   TPR11B   TPR11A   TPR7B   TPR8A   TPR10A   TPR11B   TPR11A   TPR7A   TPR7B   TPR8A C-box binding site mutant with the Apc1 300s loop deleted. An elongated loop density (dark green) for the Apc1 auto-inhibitory (AI) segment was observed in the apo unphosphorylated state (e), but the density is absent in apo phosphorylated APC/C (f). Deletion of the Apc1 300s loop shows a similar loss of C-box site-associated density (g). 5) . Deletion of the Apc1 300s loop activated the APC/C without phosphorylation (lanes 6, 7), and kinase treatment of APC/C ∆Apc1-300s did not enhance APC/C activity. The APC/C ∆Apc3-loop mutant showed similar activity as unphosphorylated APC/C (lanes 10, 11 versus 2, 3 and 4, 5), but had reduced activation by phosphorylation. Nevertheless, deletion of both Apc1 300s and Apc3 loops (APC/C ∆Apc1-300s;Apc3-loop ) restored activity to that of wild-type (WT) phosphorylated APC/C and unphosphorylated APC/C ∆Apc1-300s (lanes 14-17). b, Identification of the Apc1 autoinhibitory segment occupying the C-box binding site by assessing the inhibitory effect of eight peptides spanning the Apc1 300s loop. A single peptide (peptide 7, residues 361-380) suppressed the activity of APC/C ∆Apc1-300s (lane 9), indicating that this peptide blocks the C-box binding site. A control with wild-type unphosphorylated APC/C ( unp APC/C WT ) is in lane 11. c, The Apc1 auto-inhibitory (AI) segment (peptide 7, residues 361-380) shares sequence similarity with Cdc20 C box . A model for the auto-inhibitory segment (green) was fitted into the EM density of the apo unphosphorylated APC/C map (grey). Arg368 overlaps with the crucial Arg78 of Cdc20 C box (purple, right panel). The flanking serines shown to be phosphorylated are highlighted as red spheres. Ser377 is outside the observed EM density. d, Mutation of a single Arg368 residue (APC/C Apc1-R368E ) or mutating its four neighbouring serine residues (Ser364, Ser372, Ser373, Ser377) to glutamates (APC/C Apc1-4S/E ) activated the APC/C without phosphorylation. 30 nM Cdc20 was used for the assay in a and 20 nM Cdc20 for the assays in b and d. Experiments in a and d were replicated three times and in b five times. See Supplementary Fig. 1 for gel source data.
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Cdk-cyclin-Cks -4) , whereas it markedly reduced APC/C Cdc20 activity (lanes 5-8) . The activity assay was performed with phosphorylated wild-type (WT) APC/C and substrate Hsl1 at a coactivator concentration of 10 nM. This experiment was replicated three times. See Supplementary  Fig. 1 for gel source data. c, d , EM reconstruction of APC/C ∆Apc1-300s in complex with TAME showed densities (dark blue) for TAME (C-atoms in lime green) at both the IR tail-binding site (c), and the C-box binding site (d). Their positions overlap well with the crucial Arg78 and Tyr79 of Cdc20 C box and Ile498 and Arg499 of Cdc20 IR , thereby inhibiting Cdc20 association (Extended Data Fig. 7) .
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APC/C (Extended Data Fig. 6e ) is sufficient to compete for the autoinhibitory segment at the C-box binding site.
Our findings suggest the interesting possibility of exploiting differences in the affinities of the two coactivators for the design of inhibitors that specifically target mitotic APC/C Cdc20 and thus suppress cell proliferation. A small molecule, tosyl-l-arginine methyl ester (TAME), was reported to inhibit APC/C activation by both Cdc20 and Cdh1 through a proposed mechanism involving competition for the IR tail-binding site of coactivator 29 . However, we found that TAME is a more potent inhibitor of APC/C Cdc20 than APC/C Cdh1 (Fig. 4b) . To understand the molecular basis underlying this inhibition, we determined the structure of APC/C ∆Apc1-300s in complex with TAME (Extended Data Table 1 ). We observed TAME density not only at the IR tail-binding site, but also at the C-box binding site (Fig. 4c, d ). This is consistent with the structural similarities of the IR tail and C-box bindings sites of Apc3A and Apc8B, respectively 23 , although there are critical differences. In Apc3A, TAME is reminiscent of the Ile-Arg motif of the coactivator IR tail, whereas in Apc8B, TAME resembles the Arg-Tyr/Phe of the coactivator C box (Extended Data Fig. 7) . The mechanism of TAME inhibition of APC/C Cdc20 through a tosyl-Arg motif to block the Cdc20 C box binding site is reminiscent of the Apc1 auto-inhibitory segment that is displaced by APC/C phosphorylation. Both utilize a common structural motif (Arg-aromatic) that mimics Arg78 and Tyr79 of Cdc20 C box to exploit the lower (relative to Cdh1) affinity of Cdc20 for the APC/C.
How phosphorylation regulates mitotic APC/C activation by Cdc20 has been a long-standing puzzle. Our in vitro studies show that of almost 150 phosphorylation sites in mitotic APC/C, only a few in Apc1 directly regulate Cdc20 binding through displacement of the auto-inhibitory segment. This work has relevance to understanding the control of other large multimeric complexes by multi-site phosphorylation.
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adding SDS/PAGE loading dye. Reactions were analysed by 4-12% NuPAGE Bis-Tris gels followed by western blotting with an antibody against the His-tag of ubiquitin (Clonetech cat. code: 631212).
For the chimaeric Cdh1-Cdc20 assay, the following domain boundaries were used to generate chimaeric Cdh1-Cdc20 proteins: Cdh1 NTD (residues 1-168), Cdh1 WD40 (residues 169-475), Cdh1 IR (residues 476-496), Cdc20 NTD (residues 1-165), Cdc20 WD40 (residues 166-475), Cdc20 IR (residues 476-499). 10 nM of the chimaeric proteins were used in the assay. Peptide and TAME assays. Eight peptides (Designer BioScience) spanning the Apc1 300s loop were synthesized for identification of the Apc1 auto-inhibitory segment. Each peptide contains 20 amino acids, with a ten-residue overlap with the neighbouring peptides: peptide 1 (LTAHLRSLSKGDSPVTSPFQ); peptide 2 (GDSPVTSPFQNYSSIHSQSR); peptide 3 (NYSSIHSQSRSTSSPSLHSR); peptide 4 (STSSPSLHSRSPSISNMAAL); peptide 5 (SPSISNMAALSRAHSPALGV); peptide 6 (SRAHSPALGVHSFSGVQRFN); peptide 7 (HSFSGVQRFNISSHNQSPKR) and peptide 8 (ISSHNQSPKRHSISHSPNSN). The following mutant peptides of peptide 7 were used to assess the relief of auto-inhibition: peptide R368E (HSFSGVQEFNISSHNQSPKR), peptide 4S/E (HSFEGVQRFNIEEHNQEPKR) and peptide pS377 (HSFSGVQRFNISSHNQphosphoSPKR). The peptides were dissolved at a concentration of 10 mM in 100% dimethylsulfoxide (DMSO) and diluted using the APC/C gel-filtration buffer. The ubiquitination assay was performed using a final concentration of 200 μ M peptide. The TAME assay was performed at a similar condition using 0.5-3 mM TAME and the substrate Hsl1. Size-exclusion chromatography to assess coactivator binding. Purified APC/C samples (1 mg ml
) were incubated with either Cdh1 or Cdc20 at a molar ratio of 1:1.5 on ice for 30 min. The sample was spun down at 13,000 r.p.m. for 5 min to remove any precipitates or aggregates before injecting onto a Superose 6 3.2/300 column using the Microakta system. The eluted peak fractions were analysed by SDS-PAGE and western blotting. Mass spectrometry. Purified proteins were prepared for mass spectrometric analysis by in solution enzymatic digestion, without prior reduction and alkylation. Protein samples were digested with trypsin or elastase (Promega), both at an enzyme to protein ratio of 1:20. The resulting peptides were analysed by nano-scale capillary LC-MS/MS using an Ultimate U3000 HPLC (ThermoScientific Dionex) to deliver a flow of approximately 300 nl min −1 . A C18 Acclaim PepMap100 5 μ m, 100 μ m × 20 mM nanoViper (ThermoScientific Dionex), trapped the peptides before separation on a C18 Acclaim PepMap100 3 μ m, 75 μ m × 250 mM nanoViper (ThermoScientific Dionex, San Jose, USA). Peptides were eluted with a 90 min gradient of acetonitrile (2% to 50%). The analytical column outlet was directly interfaced via a nano-flow electrospray ionization source, with a hybrid quadrupole orbitrap mass spectrometer (Q-Exactive Plus Orbitrap, ThermoScientific). LC-MS/MS data were then searched against an in-house LMB database using the Mascot search engine (Matrix Science) 31 , and the peptide identifications validated using the Scaffold program (Proteome Software Inc.) 32 . All data were additionally interrogated manually. Electron microscopy. Freshly purified APC/C samples were first visualized by negative-staining EM to check the sample quality and homogeneity and to get initial low-resolution reconstructions. Micrographs were recorded on an FEI Spirit electron microscope at an accelerating voltage of 120 kV and at a defocus of approximately − 1.5 μ m. For cryo-EM, 2-μ l aliquots of the sample at ~ 0.15 mg ml −1 were applied onto the Quantifoil R2/2 grids coated with a layer of continuous carbon film (approximately 50 Å thick). Grids were treated with a 9:1 argon:oxygen plasma cleaner for 20 to 40 s before use. The grids were incubated for 30 s at 4 °C and 100% humidity before blotting for 5 s and plunging into liquid ethane using an FEI Vitrobot III. The grids were loaded into an FEI Tecnai Polara electron microscope at an acceleration voltage of 300 kV. Micrographs were taken using EPU software (FEI) at a nominal magnification of 78,000 which yields a pixel size of 1.36 Å per pixel. They were recorded by an FEI Falcon III direct electron detector with a defocus range of − 2.0 to − 4.0 μ m. The exposure time for each micrograph was 2 s at a dose rate of 27 electrons per Å 2 per s. 34 movie frames were recorded for each micrograph as described 33 . Image processing. All movie frames were aligned by the motioncorr program 34 before subsequent processing. First, the contrast transfer function parameters were calculated with CTFFIND3 or Gctf 35, 36 . Particles in 264 pixels × 264 pixels were selected by automatic particle picking in RELION 1.4 (ref. 37) . The following steps were performed to exclude bad particles from the data set: (1) automatically picked particles in each micrograph were screened manually to remove ice contaminations 38 ; (2) after particle sorting in RELION, particles with poor similarity to reference images were deleted; (3) 2-dimensional classification was performed and particles in bad classes with poorly recognizable features were excluded. The remaining particles were divided into six classes using three-dimensional
METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Expression and purification of recombinant human APC/C. The genes for recombinant human APC/C were cloned into a modified MultiBac system, expressed and purified as described 30 . The C terminus of Apc4 was fused to a TEV (tobacco etch virus)-cleavable StrepII× 2 tag. Protein kinase purification. All four proteins (Cdk2, cyclin A3 (residues 174-432), Cks2 and Plk1 (residues 37-338)) for the kinases were expressed individually in BL21 (DE3) Star cells at 18 °C overnight. Pellets containing GSTtagged Cdk2, His-tagged cyclin A3 and His-SUMO-tagged Cks2 were combined and resuspended in the CDK lysis buffer (50 mM Tris/HCl pH 7.4, 180 mM NaCl, 5% glycerol and 2 mM DTT) supplemented with 0.1 mM PMSF, lysozyme, 5 units per ml benzonase and Complete EDTA-free protease inhibitors (Roche). After sonication, the cells were centrifuged at 20,000 r.p.m. for 1 h at 4 °C and the supernatant was incubated with the Glutathione Sepharose 4B (GE Healthcare) for 3 h at 4 °C. The resins were washed with the CDK lysis buffer and the GSTtag of Cdk2 was cleaved off with 3C PreScission protease overnight at 4 °C. The flow-through from the resins was collected and TEV-cleaved overnight at 4 °C. Finally, the protein complex was purified by a Superdex200 16/60 column (GE Healthcare).
The Polo kinase Plk1 with an N-terminal His-MBP tag was purified with a HisTrap HP column (GE Healthcare) in the PLK lysis buffer (50 mM Tris/HCl pH 7.5, 300 mM NaCl, 20 mM imidazole, 5% glycerol and 2 mM β -mercaptoethanol). The column was washed intensively with high-salt buffer (50 mM Tris/HCl pH 7.5, 1 M NaCl, 20 mM imidazole, 5% glycerol and 2 mM β -mercaptoethanol). Proteins were eluted with a gradient of the elution buffer (50 mM Tris/HCl pH 7.5, 300 mM NaCl, 300 mM imidazole, 5% glycerol and 2 mM β -mercaptoethanol) followed by TEV-cleavage overnight at 4 °C. The sample was re-applied onto the HisTrap HP column to remove the His tag, uncleaved proteins and nickel contaminations. The collected flow-through was concentrated and loaded onto a Superdex75 16/60 column (GE Healthcare) for final purification. In vitro phosphorylation of recombinant human APC/C. Concentrated APC/C after Resource Q (GE Healthcare) was treated with Cdk2-cyclin A3-Cks2 and Plk1 in a molar ratio of 1:1.5 (APC/C: kinases) in a reaction buffer of 40 mM HEPES pH 8.0, 10 mM MgCl 2 and 0.6 mM DTT with 5 mM ATP and 50 mM NaF. The reaction mixture was incubated at 30 °C for 30 min before the final purification step by a Superose 6 3.2/300 column (GE Healthcare) in the APC/C gel-filtration buffer (20 mM HEPES pH 8.0, 150 mM NaCl, 0.5 mM TCEP). Expression and purification of the substrate Cdk2-cyclin A2-Cks2 and Cdc20. Full-length human cyclin A2 was cloned into the pETM41 vector with an N-terminal His-MBP tag. The protein was expressed in BL21 (DE3) Star cells at 18 °C overnight. Pellets containing Cdk2, cyclin A2 and Cks2 were co-lysed for purification following a similar protocol as for the kinase purification.
Full-length human Cdc20 was cloned into a modified pFastBac HTa vector with an N-terminal His-MBP tag. The generated virus was amplified and expressed in Sf9 cells. Harvested cell pellets were resuspended in Cdc20 lysis buffer (50 mM HEPES pH 7.8, 500 mM NaCl, 30 mM imidazole, 10% glycerol and 0.5 mM TCEP) supplemented with 0.1 mM PMSF, 5 units per ml benzonase and Complete EDTAfree protease inhibitors and loaded onto a HisTrap HP column (GE Healthcare). Proteins were eluted with a gradient to 300 mM imidazole. Collected peak fractions were TEV-cleaved overnight in the dialysis bag (cut-off 6-8 kDa) against the dialysis buffer (50 mM HEPES, pH 7.8, 300 mM NaCl, 5% glycerol and 0.5 mM TCEP) at 4 °C. The protein was re-applied onto the HisTrap HP column and the flow-through was collected. Complex formation of APC/C Cdc20-Hsl1 and APC/C ∆Apc1-300s-TAME . In vitro phosphorylated APC/C was treated with 40 μ M CDK1/2 inhibitor iii (ENZO Life Sciences) before incubating with purified Cdc20 and Hsl1 (with a molar ratio of 1:1.5:2) on ice. The complex was purified by a Superose 6 3.2/300 column using the Microakta system. TAME (Sigma-Aldrich) was dissolved in 50% DMSO and 50% APC/C gelfiltration buffer at a concentration of 1 M. 4 mM TAME was added to purified APC/C ∆Apc1-300s and incubated on ice for 1 h before freezing cryo-grids. Ubiquitination assays. The ubiquitination assay was performed with 60 nM recombinant human APC/C, 90 nM UBA1, 300 nM UbcH10, 300 nM Ube2S, 70 μ M ubiquitin, 2 μ M substrate Cdk2-cyclin A2-Cks2 or Hsl1, 5 mM ATP, 0.25 mg ml −1 BSA, 15 μ M CDK1/2 inhibitor iii and different concentrations of purified human Cdc20 (5-30 nM) or Cdh1 (5-30 nM) in a 10 μ l reaction volume with 40 mM HEPES pH 8.0, 10 mM MgCl 2 and 0.6 mM DTT (figure legends indicate the exact coactivator concentration used in each assay). Reaction mixtures were incubated at room temperature for various time points and terminated by
